Small-molecule interferon inducers. Toward the comprehension of the molecular determinants through ligand-based approaches

Journal of Chemical Information and Modeling

Volumn 49, Issue 7, 2009, Pages 1777-1786

  Musmuca, Ira ^a   Simeoni, Silvia ^a   Caroli, Antonia ^a   Ragno, Rino ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; BIOACTIVITY; GLYCOPROTEINS; HYDROGEN BONDS; LIGANDS; MOLECULAR GRAPHICS; PROBES;

ALIGNMENT PROTOCOLS; HYDROGEN BONDING INTERACTIONS; LOW MOLECULAR WEIGHT; MOLECULAR DETERMINANTS; PHARMACOPHORE MODELING; PREDICTIVE PERFORMANCE; SMALL MOLECULES; THREE-DIMENSIONAL QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

COMPUTATIONAL CHEMISTRY;

INTERFERON INDUCING AGENT; LIGAND;

ARTICLE; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; DRUG DESIGN; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

COMPUTER SIMULATION; DRUG DESIGN; INTERFERON INDUCERS; LIGANDS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 68149158838     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci900065a     Document Type: Article

References (53)

1. Bartenschlager, R.; Lohmann, V. Replication of hepatitis C virus. J. Gen. Virol. 2000, 81, 1631-1648.
2. Penin, F.; Dubuisson, J.; Rey, F. A.; Moradpour, D.; Pawlotsky, J. M. Structural biology of hepatitis C virus. Hepatology 2004, 39, 5-19.
3. Hirota, K.; Kazaoka, K.; Niimoto, I.; Kumihara, H.; Sajiki, H.; Isobe, Y.; Takaku, H.; Tobe, M.; Ogita, H.; Ogino, T.; Ichii, S.; Kurimoto, A.; Kawakami, H. Discovery of 8-hydroxyadenines as a novel type of interferon inducer. J. Med. Chem. 2002, 45, 5419-5422.
4. Saito, I.; Miyamura, T.; Ohbayashi, A.; Harada, H.; Katayama, T.; Kikuchi, S.; Watanabe, Y.; Koi, S.; Onji, M.; Ohta, Y.; et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 6547-6549.
5. Koike, K. Antiviral treatment of hepatitis C: present status and future prospects. J. Infect. Chemother. 2006, 12, 227-232.
6. Chevaliez, S.; Pawlotsky, J. M. Interferon-based therapy of hepatitis C. Adv. Drug Delivery Rev. 2007, 59, 1222-1241.
7. Hayashi, N.; Takehara, T. Antiviral therapy for chronic hepatitis C: past, present, and future. J. Gastroenterol. 2006, 41, 17-27.
8. Dymock, B. W. Emerging therapies for hepatitis C virus infection. Expert. Opin. Emerging. Drugs. 2001, 6, 13-42.
9. Stringfellow, D. A.; Glasgow, L. A. Tilorone hydrochloride: an oral interferon-inducing agent. Antimicrob. Agents. Chemother. 1972, 2, 73-78.
10. Mayer, G. D.; Krueger, R. F. Tilorone hydrochloride: mode of action. Science 1970, 169, 1214-1215.
11. Siminoff, P.; Bernard, A. M.; Hursky, V. S.; Price, K. E. BL-20803, a new, low-molecular-weight interferon inducer. Antimicrob. Agents. Chemother. 1973, 3, 742-743.
12. Glaz, E. T.; Szolgay, E.; Stoger, I.; Talas, M. Antiviral activity and induction of interferon-like substance by quinacrine and acranil. Antimicrob. Asents Chemother. 1973, 3, 537-541.
13. Hoffman, W. W.; Korst, J. J.; Niblack, J. F.; Cronin, T. H. N. N-dioctadecyl-N′,N′-bis(2-hydroxyethyl) propanediamine: antiviral activity and interferon stimulation in mice. Antimicrob. Agents. Chemother. 1973, 3, 498-502.
14. Nichol, F. R.; Weed, S.D.; Underwood, G. E. Stimulation of murine interferon by a substituted pyrimidine. Antimicrob. Aeents Chemother. 1976, 9, 433-439.
15. Tamm, I.; Sehgal, P. B. A comparative study of the effects of certain halogenated benzimidazole ribosides on RNA synthesis, cell proliferation, and interferon production. J. Exp. Med. 1977, 145, 344-356.
16. Taylor, J. L.; Schoenherr, C. K.; Grossberg, S. E. High-yield interferon induction by 10-carboxymethy1-9-acridanone in mice and hamsters. Antimicrob. Aeents Chemother. 1980, 18, 20-26.
17. Wierenga, W.; Skulnick, H. I.; Stringfellow, D. A.; Weed, S. D.; Renis, H. E.; Eidson, E. E. 5-substituted 2-amino-6-pheny1-4(3H)-pyrimidi-nones. Antiviral- and interferon-inducing agents. J. Med. Chem. 1980, 23, 237-239.
18. Dockrell, D. H.; Kinghorn, G. R. Imiquimod and resiquimod as novel immunomodulators. J. Antimicrob. Chemother. 2001, 48, 751-755.
19. Hemmi, H.; Kaisho, T.; Takeuchi, O.; Sato, S.; Sanjo, H.; Hoshino, K.; Horiuchi, T.; Tomizawa, H.; Takeda, K.; Akira, S. Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 2002, 3, 196-200.
20. Strominger, N. L.; Brady, R.; Gullikson, G.; Carpenter, D. O. Imiquimod-elicited emesis is mediated by the area postrema, but not by direct neuronal activation. Brain Res. Bull. 2001, 55, 445-451.
21. Kurimoto, A.; Tobe, M.; Ogita, H.; Ogino, T.; Takaku, H.; Ichii, S.; Kawakami, H.; Isobe, Y. Prodrugs of 9-benzy1-8-hydroxy-2-(2-hydroxyethylthio) adenine: potent interferon inducing agents in monkeys. Chem. Pharm. Bull. (Tokyo) 2004, 52, 466-469.
22. Clark, M.; Cramer, R. D., III; Jones, D. M.; Patterson, D. E.; Simeroth, P. E. Comparative molecular field analysis (CoMFA). 2. Toward its use with 3D-structural databases. Tetrahedron Comput. Methodol. 1990, 3, 47-59.
23. Cramer, R. D., III; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
24. Cramer, R. D., III; Wold, S. B. Comparative molecular field analysis (CoMFA). PCT Int. Appl. US 88-237491, 1991.
25. Cruciani, G.; Watson, K. A. Comparative Molecular Field Analysis Using GRID Force-Field and GOLPE Variable Selection Methods in a Study of Inhibitors of Glycogen Phosphorylase b. J. Med. Chem. 1994, 37, 2589-25601.
26. Pastor, M.; Cruciani, G.; Watson, K. A. A strategy for the incorporation of water molecules present in a ligand binding site into a three-dimensional quantitative structure-activity relationship analysis. J. Med. Chem. 1997, 40, 4089-4102.
27. Ortiz, A. R.; Pastor, M.; Palomer, A.; Cruciani, G.; Gago, F.; Wade, R. C. Reliability of comparative molecular field analysis models: effects of data scaling and variable selection using a set of human synovial fluid phospholipase A2 inhibitors. J. Med. Chem. 1997, 40, 1136-1148.
28. Cruciani, G.; Clementi, S.; Pastor, M. GOLPE-guided region selection. Perspect. Drug Discovery Des. 1998, 12/13/14, 71-86.
29. Sippl, W.; Contreras, J. M.; Parrot, I.; Rival, Y. M.; Wermuth, C. G. Structure-based 3D QSAR and design of novel acetylcholinesterase inhibitors. J. Comput.-Aided Mol. Des. 2001, 15, 395-410.
30. Audouze, K.; Nielsen, E. O.; Peters, D. New series of morpholine and 1,4-oxazepane derivatives as dopamine D4 receptor ligands: synthesis and 3D-QSAR model. J. Med. Chem. 2004, 47, 3089-3104.
31. Isobe, Y.; Kurimoto, A.; Tobe, M.; Hashimoto, K.; Nakamura, T.; Norimura, K.; Ogita, H.; Takaku, H. Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers. J. Med. Chem. 2006, 49, 2088-2095.
32. Isobe, Y.; Tobe, M.; Ogita, H.; Kurimoto, A.; Ogino, T.; Kawakami, H.; Takaku, H.; Sajiki, H.; Hirota, K.; Hayashi, H. Synthesis and structure-activity relationships of 2-substituted-8-hydroxyadenine derivatives as orally available interferon inducers without emetic side effects. Bioorg. Med. Chem. 2003, 11, 3641-3647.
33. Kurimoto, A.; Ogino, T.; Ichii, S.; Isobe, Y.; Tobe, M.; Ogita, H.; Takaku, H.; Sajiki, H.; Hirota, K.; Kawakami, H. Synthesis and structure-activity relationships of 2-amino-8-hydroxyadenines as orally active interferon inducing agents. Bioorg. Med. Chem. 2003, 11, 5501-5508.
34. Kurimoto, A.; Ogino, T.; Ichii, S.; Isobe, Y.; Tobe, M.; Ogita, H.; Takaku, H.; Sajiki, H.; Hirota, K.; Kawakami, H. Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities. Bioorg. Med. Chem. 2004, 12, 1091-1099.
35. Gerster, J. F.; Lindstrom, K. J.; Miller, R. L.; Tomai, M. A.; Birmachu, W.; Bomersine, S. N.; Gibson, S. J.; Imbertson, L. M.; Jacobson, J. R.; Knafla, R. T.; Maye, P. V.; Nikolaides, N.; Oneyemi, F. Y.; Parkhurst, G. J.; Pecore, S. E.; Reiter, M. J.; Scribner, L. S.; Testerman, T. L.; Thompson, N. J.; Wagner, T. L.; Weeks, C. E.; Andre, J. D.; Lagain, D.; Bastard, Y.; Lupu, M. Synthesis and structure-activity-relationships of lH-imidazo[4,5-c]quinolines that induce interferon production. J. Med. Chem. 2005, 48, 3481-3491.
36. Schuttelkopf, A. W.; van Aalten, D. M. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallosr., Sect. D: Biol. Crystallogr. 2004, 60, 1355-1363.
37. van Aalten, D. M.; Bywater, R.; Findlay, J. B.; Hendlich, M.; Hooft, R. W.; Vriend, G. PRODRG, a program for generating molecular topologies and unique molecular descriptors from coordinates of small molecules. J. Comput.-Aided Mol. Des. 1996, 10, 255-262.
38. Berendsen, H. J. C.; van der Spoel, D.; van Drunen, R. GROMACS: A message-passing parallel molecular dynamics implementation. Comput. Phys. Commun. 1995, 91, 43-56.
39. Folkers, G.; Merz, A.; Rognan, D. CoMFA: Scope and Limitations. In 3D QSAR in Drug Design: Theory Methods and Applications; Kubinyi, H., Ed.; ESCOM Science Publishers B.V.: Leiden, The Netherlands, 1993; pp 583-618.
40. Zhao, B.; Rong, Y. Z.; Huang, X. H.; Shen, J. S. Experimental and theoretical study on the structure and electronic spectra of imiquimod and its synthetic intermediates. Bioorg. Med. Chem. Lett. 2007, 17, 4942-4946.
41. Jain, A. N. Ligand-based structural hypotheses for virtual screening. J. Med. Chem. 2004, 47, 947-961.
42. Jain, A. N. Morphological similarity: a 3D molecular similarity method correlated with protein-ligand recognition. J. Comput.-Aided Mol. Des. 2000, 14, 199-213.
43. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 1985, 28, 849-857.
44. Wade, R. C.; Clark, K. J.; Goodford, P. J. Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. 1. Ligand probe groups with the ability to form two hydrogen bonds. J. Med. Chem. 1993, 36, 140-147.
45. Wade, R. C.; Goodford, P. J. Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. 2. Ligand probe groups with the ability to form more than two hydrogen bonds. J. Med. Chem. 1993, 36, 148-156.
46. Geladi, P.; Kowalski, B. R. Partial least-squares regression: a tutorial. Anal. Chim. Acta 1986, 185, 1-17.
47. Ragno, R.; Simeoni, S.; Valente, S.; Massa, S.; Mai, A. 3-D QSAR Studies on Histone Deacetylase Inhibitors. A GOLPE/GRID Approach on Different Series of Compounds. J. Chem. Inf. Model. 2006, 46, 1420-1430.
48. Cruciani, G.; Baroni, M.; Clementi, S.; Costantino, G.; Riganelli, D.; Skagerberg, B. Predictive ability of regression models. Part I. Standard deviation of prediction errors (SDEP). J. Chemom. 1992, 6, 335-346.
49. Clark, M.; Cramer, R. D., III. The probability of chance correlation using partial least squares (PLS). Quant. Struct.-Act. Relat. 1993, 12, 137-145.
50. 2! J. Mol. Graph. Model. 2002, 20, 269-276.
51. Czarniecki, M. Small Molecule Modulators of Toll-like Receptors. J. Med. Chem. 2008, 51, 6621-6626.
52. Chong, L. S.; Desai, M. C.; Gallagher, B.; Graupe, M.; Halcomb, R. L.; Yang, H.; Zhang, J. R. Preparation of purine and thiadeazapurine phosphonate derivatives as modulators of toll-like receptor 7. PCT Int. Appl. WO 2008005555, 2008.
53. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera - a visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25, 1605-12.